Why the study?
Preclinical studies showed that asparagine deprivation enhances T cell antitumour responses, but clinical application remained to be evaluated.
Does L-asparaginase combined with anti-PD-1 therapy improve tumour response in patients with recurrent metastatic nasopharyngeal carcinoma?
Does L-asparaginase combined with anti-PD-1 therapy improve tumour response in patients with recurrent metastatic nasopharyngeal carcinoma?
L-asparaginase enhances the efficacy of PD-1 blockade in refractory nasopharyngeal carcinoma by promoting ROS-mediated metabolic adaptations and effector functions in CD8+ T cells.
Hypothesis-generating salvage option in ICB-refractory NPC; leaves open randomized trials before any practice change.
Preclinical studies have shown that asparagine deprivation enhances T cell antitumour responses. Here we apply compassionate use of l -asparaginase, usually employed to treat blood malignancies, on patients with recurrent metastatic nasopharyngeal carcinoma. The use of l -asparaginase notably enhances immune-checkpoint blockade therapy in patients by strengthening CD8 + T cell fitness. Our study shows that this combination is a promising avenue for clinical application and provides further mechanistic insight into how asparagine restriction rewires T cell metabolism.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: